Buy CJC-1295 No DAC Online
CJC-1295 No DAC is a short-acting growth-hormone-releasing hormone (GHRH) analogue commonly known as Modified GRF 1-29. It is designed to stimulate the body’s own growth-hormone signaling and is frequently researched alongside growth-hormone secretagogues such as ipamorelin.
Unlike CJC-1295 with DAC, the No-DAC form does not contain the Drug Affinity Complex, resulting in a much shorter duration of action.
Product Information
CJC-1295 No DAC acts on the GHRH receptor in the pituitary and promotes growth hormone release. Increased GH signaling can subsequently influence IGF-1, protein metabolism, tissue growth, and recovery pathways.
It is particularly popular in research combinations because its short action allows it to be paired with another secretagogue to create a more pronounced pulsatile GH response.
How Does It Work?
CJC-1295 No DAC activates the GHRH receptor, encouraging pituitary GH release and downstream IGF-1 signaling.
Benefits
Supports Growth-Hormone Research
CJC-1295 No DAC directly targets the GHRH pathway responsible for stimulating pituitary growth-hormone secretion, making it useful in research into the GH/IGF-1 axis.
IGF-1 Research
Growth hormone stimulates hepatic IGF-1 production, linking CJC-1295 research to muscle, bone, tissue, and metabolic signaling.
Pulsatile GH Research
Because No DAC is short-acting, researchers can investigate pulsatile GH signaling rather than the prolonged exposure associated with long-acting CJC-1295.
Combination Research
CJC-1295 No DAC is commonly investigated alongside peptides such as ipamorelin and GHRP-6, allowing researchers to examine interactions between GHRH and GH-secretagogue pathways.
Side Effects
Reported effects include water retention, headache, fatigue, tingling, joint discomfort, increased appetite, and changes in glucose regulation. Injection-site reactions can also occur.
Dosage
Current research-community protocols commonly report 100–300 mcg per administration, one to three times daily, particularly when paired with a GH secretagogue. No-DAC dosing should not be confused with the much less frequent dosing used for CJC-1295 with DAC.
Research References
Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol. 2026.
PubMed — GH/IGF-1 Peptide Review
Purerawz Disclaimer
Purerawz does not sell, manufacture, stock, dispense, or directly supply any of the products discussed on this website. Purerawz is an independent information and affiliate platform. Where available, links may direct readers to independent third-party providers, and Purerawz may receive a commission from qualifying purchases at no additional cost to the reader.
The information provided is for educational and informational purposes only. Dosage figures may reflect published research protocols, historical clinical use, or reported community practices and should not be interpreted as personalized medical instructions. Research findings—particularly those from animal, cellular, or small early-stage studies—do not establish that a product is safe or effective for every individual or condition.
